IMDX Stock Analysis: Buy, Sell, or Hold?
IMDX - Insight Molecular Diagnostics Inc. Common Stock
$3.26
-0.31 (-8.57%)
▼
5d:
-18.63%
30d:
-45.84%
90d:
-48.9%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 11, 2026
Get Alerted When IMDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMDX is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMDX is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMDX is currently trading at $3.25, which is considered oversold relative to its 30-day fair value range of $4.15 to $5.63.
Technical Outlook: Technically, IMDX is in a downtrend. The price is currently testing key support at $3.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.6% recently.
Market Sentiment: IMDX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+134.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMDX is in a downtrend. The price is currently testing key support at $3.44. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.6% recently.
Market Sentiment: IMDX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.33 (+134.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.15 -
$5.63
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.6%)
- BULLISH: Trading 134.1% below Wall St target ($8.33)
- WARNING: Recommendation downgraded due to -18.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.15 -
$5.63
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.47
(14.3%)
Support & Resistance Levels
Support Level
$3.44
Resistance Level
$4.97
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.24
Wall Street Target
$8.33
(+134.1%)
Revenue Growth (YoY)
126.1%
Share & Embed Analysis
Last updated: March 30, 2026 10:14 AM ET
Data refreshes hourly during market hours. Next update: 11:14 AM
Data refreshes hourly during market hours. Next update: 11:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMDX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Broadwood Partners, L.P.
BUY
521739 shares
2026-02-10
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 58 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 60 HOLD |